Risk factors for central nervous system metastasis in patients with metastatic breast cancer

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 155-161

  Sezgin, Canfeza ^a   Gokmen, Erhan ^a   Esassolak, Mustafa ^a   Ozdemir, Necmettin ^a   Goker, Erdem ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Breast cancer; Central nervous system metastasis; Lung metastasis; p53; Risk factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER RELAPSE; CANCER RISK; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36248945607     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698034     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts and Figures 2005. American Cancer Society: Atlanta, GA, 2005.
2. Honig SF. Treatment of metastatic disease. In: Harris JR, et al. (eds). Diseases of the Breast. Lippincott-Raven Publishers: Philadelphia, 1996, pp. 669-734.
3. Takakura K, et al. Metastatic Tumors of the Central Nervous System. Igaku-Shoin: Tokyo, 1982.
4. DiStefano A, et al. The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-1918.
5. Crivellari D, et al. International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12:353-356.
6. Shmueli E, Wigler N, Inbar M: Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004;40:379-382.
7. Clayton AJ, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643.
8. Miller KD, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-1077.
9. Slimane K, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004;15(11):1640-1644.
10. Auperin A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
11. Stuschke M, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999;17:2700-2709.
12. Middleton LP, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000;24:1650-1656.
13. Sjöström J, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000;6:3103-3110.
14. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 2001;54(7):543-549.
15. Paik S, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst (Bethesda) 2002;94:852-854.
16. Samaan NA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554-560.
17. Stewart JF, et al. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981;17:449-453.
18. Crivellari D, et al. International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12:353-356.
19. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncologist 2003;8:398-410.
20. Sparrow GE, Rubens RD. Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin Oncol 1981;7:291-301.
21. Taichman RS, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
22. Fernandis AZ, et al. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004;23:157-167.
23. Scotton CJ, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930- 5938.
24. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 2003;105: 186-189.
25. Muller A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
26. Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2004;2:327-338.
27. Tanabe S, et al. Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol 1997;159:905-911.
28. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 1998;69:99-104.
29. Lower EE, et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003;4:114-119.
30. Bendell JC, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972-2977.
31. Hill KA, Sommer SS. P53 as a mutagen test in breast cancer. Environ Mol Mutagen 2002;39:216-227.
32. Thor AD, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-854.
33. Fitzgibbons PL, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
34. Howard EM, et al. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population. Int J Clin Oncol 2004;9:154-160.
35. Charpin C, et al. E-cadherin quantitative immunocytochemical assays in breast carcinomas. J Pathol 1997;181(3):294-300.
36. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-119.
37. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator [Review]. Science 1991;251: 1451-1455.
38. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993;55:371-374.
39. Linderholm BK, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-2260.
40. Yano S, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60:4959-4967.
41. Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 2003;278(7):5277-5284.
42. Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004;21(2):107-118.